Summary
For Year 2026-27, Speciality Medicines reports the following shareholding: Total Promoters at 43.43%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0.24%, Domestic Institutional Investors at 0%, and Retail at 56.33%. This breakdown provides a quick snapshot of ownership distribution for Speciality Medicines in 2026-27.
Speciality Medicines FAQs
As of 04-2026, the promoter shareholding in Speciality Medicines stands at 43.43% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Speciality Medicines is 0.24% and 0% respectively.
The retail shareholding of the Speciality Medicines is 56.33%.
Changes in shareholding patterns of Speciality Medicines can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Speciality Medicines are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Speciality Medicines Associated Pages
